LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lyell Immunopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)
Close on Oct 19, 2026
- Market cap
- $205.60M
- P/E (TTM)
- –
- Dividend yield
- –
Lyell Immunopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Market Cap | $215.65M | $164.85M |
| Enterprise Value | $11.54M | $87.06M |
| PS Ratio | 7986.86 | 3.60 |
| PB Ratio | 0.92 | 2.03 |
| P/TBV Ratio | 0.92 | 2.31 |
Enterprise value
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| EV / Sales | 427.53 | 2.43 |
Income (trailing twelve months)
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Revenue | $27.00K | $57.94M |
| Operating Income | -$256.50M | -$21.44M |
| Net Income | -$248.48M | -$22.46M |
| EBITDA | -$246.98M | -$16.91M |
| EPS (Diluted) | -$12.01 | -$0.83 |
Margins
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Operating Margin | -949981.0% | -44.5% |
| Profit Margin | -920285.0% | -39.2% |
| EBITDA Margin | -914733.0% | -31.3% |
| FCF Margin | -496189.0% | -8.85% |
Returns
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -93.3% | -53.1% |
| Return on Assets (ROA) | -71.3% | -41.0% |
| Return on Invested Capital (ROIC) | -781.7% | -32.0% |
| Return on Capital Employed (ROCE) | -94.5% | -37.8% |
Growth
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -55.0% | 6.01% |
| Revenue Growth (3Y CAGR) | -92.5% | 2.25% |
| Revenue Growth (5Y CAGR) | -65.9% | 6.42% |
Balance sheet
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $204.10M | $62.42M |
| Net Cash (Debt) | $204.10M | $15.68M |
| Net Cash Per Share | $8.33 | $0.66 |
| Equity (Book Value) | $233.82M | $48.79M |
| Book Value Per Share | $9.54 | $1.36 |
| Tangible Book Value | $233.82M | $23.06M |
| Working Capital | $173.67M | $75.77M |
Financial position
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Current Ratio | 5.36 | 3.30 |
| Quick Ratio | 5.12 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$133.26M | -$12.35M |
| Capital Expenditures | -$711.00K | -$1.06M |
| Free Cash Flow | -$133.97M | -$20.28M |
| FCF Per Share | -$5.47 | -$0.42 |
Efficiency
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
Dividends and yields
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Earnings Yield | -115.2% | -22.7% |
| FCF Yield | -62.1% | -9.07% |
Shares
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Shares Outstanding | 24,505,100 | 58,179,650 |
| Shares Change (YoY) | 49.1% | 11.1% |
| Shares Change (QoQ) | 0.29% | 0.54% |
| Float | 15,808,600 | 49,173,100 |
| Shares Held by Insiders | 35.5% | 11.6% |
| Shares Held by Institutions | 48.9% | 59.4% |
Scores
| Measure | Lyell Immunopharma | Industry median |
|---|---|---|
| Altman Z-Score | -7.97 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Lyell Immunopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.